Drug news
Merck returns all rights to vernakalant to Cardiome Pharma for Atrial Fibrillation
Merck & Co has returned the global marketing and development rights to Cardiome Pharma Corporation for both the intravenous and oral formulations for the anti-arrhythmic , Brinavess (vernakalant). Merck has been marketing the intravenous form of the drug, as Brinavess, in the European Union and Latin America for the rapid conversion of recent onset Atrial Fibrillation and planned to launch the product in 30 additional countries this year.